Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 3, randomized, double-blind, multicenter study of proteinase 3 PR1 peptide mixed with montanide ISA-51 VG adjuvant [leukaemia vaccine] and administered with GM-CSF [granulocyte-macrophage colony-stimulating factor; sargramostim] in elderly patients with AML [acute myeloid leukaemia] in first complete remission or adults in second complete remission: a pivotal study.

Next Previous
X
Search
Trial Profile

A phase 3, randomized, double-blind, multicenter study of proteinase 3 PR1 peptide mixed with montanide ISA-51 VG adjuvant [leukaemia vaccine] and administered with GM-CSF [granulocyte-macrophage colony-stimulating factor; sargramostim] in elderly patients with AML [acute myeloid leukaemia] in first complete remission or adults in second complete remission: a pivotal study.

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 10 Nov 2021

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Montanide ISA-51 (Primary) ; PR1 peptide vaccine (Primary) ; Sargramostim (Primary)
  • Indications Acute myeloid leukaemia
  • Focus Registrational; Therapeutic Use

    • Most Recent Events

    • 26 Feb 2009 Status changed from recruiting to active, no longer recruiting, as reported by ClinicalTrials.gov.
    • 13 Nov 2007 Trial centres added.
    • 12 Jun 2007 New trial record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top